Skip to main content
Clinical Trials/NCT05443100
NCT05443100RecruitingNot Applicable

A Non-randomized Pilot Study of the Impact on Rehabilitation Outcomes of a Course of Whole-body Cryostimulation (WBC) Treatment on Patients With Metabolic or Neurological Diseases or Fibromyalgia

Istituto Auxologico Italiano2 sites in 1 country300 target enrollmentStarted: April 1, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
300
Locations
2
Primary Endpoint
Change from baseline blood catecholamine levels (epinephrine, norepinephrine and dopamine)

Study Overview

Brief Summary

The purpose of this clinical trial is to investigate on different types of patients the effects of 10 sessions of whole-body cryostimulation (WBC): 1) in patients with obesity (BMI > 30), we want to investigate whether WBC increases thermogenesis, basal metabolic rate (BMR), respiratory quotient (which indirectly provides an estimate of energy substrate oxidation), reduces chronic inflammatory status, fatigue and pain, and improves functional abilities and general physical and psychological capacities; 2) in patients diagnosed with fibromyalgia and/or osteoarthrytis, we want to investigate the reduction of pain, inflammatory status, increase in functional capacity and general physical and psychological abilities, and improvement in mood; 3) in neurological patients diagnosed with Parkinson's disease, Multiple Sclerosis, and Disimmune Polyneuropathies, the effects of WBC on pain, fatigue, and sleep quality are to be investigated; 4) in normal/overweight (BMI<30 kg/m2) subjects, the effects of WBC on all parameters described previously for the other protocols are to be investigated. Specifically, for all enrolled subjects, we want to assess blood catecholamine levels, investigate the effects of sympathetic response on body composition, blood pressure, heart rate, lipid profile, and physical performance. Three hundred patients admitted for a rehabilitation program (diet + physiotherapy + exercise) will be non-randomly assigned to either a group following the program (R) or a group additionally receiving ten 2-3 minute WBC sessions at -110°C over two weeks (RWBC).

Detailed Description

Introduction: Istituto Auxologico Italiano (IAI) has as its institutional mission the study, treatment and rehabilitation of patients with obesity and neurological disorders as well as translational research from bench to bedside to improve these care pathways. The validation of innovative therapeutic modalities of proven efficacy on these patients, potentially scalable to the health care system, is a signature activity of the Institute's Current Research program. IAI in Piancavallo admits 3300 rehabilitation patients with comorbid obesity, including fibromyalgia, and 480 with neurological conditions each year. Pain, chronic fatigue, poor sleep quality, inflammatory status, thymic tone deflection, and obesity have a negative impact on rehabilitation treatment. Whole-body Cryostimulation (WBC) represents an innovative method that induces increased thermogenesis by promoting weight loss, reduced inflammation and oxidative stress with therapeutic effect on fatigue, pain, thymic tone and sleep (Polish Cryomedical Society, Polish Society for Rheumatology). Exposure to cryogenic temperatures would cause activation of the sympathetic system and thus an increase in catecholamine levels, which would stimulate excess adipose tissue to convert from white, metabolically inert tissue to brown, i.e., metabolically active adipose tissue. In fact, it has been previously reported that repeated exposure to WBC reduces inflammation and oxidation, improving immunity, antioxidant activity, and insulin sensitivity, and increasing the percentage of brown adipose tissue (BAT) volume and fatty acid utilization by decreasing the percentage of adipose tissue. This would be reflected in increased tolerance to rehabilitation treatment, improved neuro-cognitive performance and psychological state. The metabolic effect of repeated cold exposure with WBC (browning of adipose tissue and increased thermogenesis) would allow, within multidisciplinary rehabilitation pathways, a better weight loss goal for functional recovery and disease progression in patients with obesity. Since the changes demonstrated at the molecular level after WBC are similar to those induced by exercise, WBC treatment would represent a potential alternative to exercise that is often poorly tolerated in patients with complicated metabolic diseases and disabling neurological conditions and thus a complementary innovative nonpharmacological rehabilitation strategy within a rehabilitation pathway.

Participants: Using a consecutive sampling technique, the investigators will recruit patients for a comprehensive, multidisciplinary rehabilitation program for obesity. Patients of both sex, age 18-65 years with BMI > 35 kg/m2 will be selected and consecutively evaluated for inclusion in the protocol. Exclusion criteria are: severe psychiatric conditions, acute respiratory disease, acute cardiovascular disease, unstable hypertension, cold intolerance, claustrophobia, pregnancy, recent modification of usual drug treatment, previous treatment with WBC, weight loss in the last 3 months, and body temperature greater than 37.5°C. All patients will perform a multidisciplinary rehabilitation program (diet + exercise and physiotherapy).

Study design: Patients will be assigned to either a "rehabilitation + WBC" (RWBC) or "rehabilitation" intervention (R) group in a consecutive, non-randomized manner until the total sample for each group is reached (15 subjects per group).

Anthropometric values, body composition, plasma catecholamine concentration, demographic and hematological analyses, muscle strength and functional values of both groups will be assessed at admission (PRE-T0) and at discharge (POST-T10), two weeks later, for both groups within the hospital facility. They will undergo 10 sessions of WBC over two weeks (1 treatment per day, Monday through Friday, before exercise classes and physical therapy). Skin temperatures will be recorded immediately before and after each WBC exposure. Description of the WBC session: Study participants will be exposed to extremely cold, dry air at -110°C for 2-3 minutes in a cryochamber (Artic, CryoScience, Rome. The first WBC session will last 1 minute at -110°C to familiarize the patient with the cryochamber temperature, while all subsequent treatments will last 2 minutes. The patient's skin surface temperature at the neck, quadriceps, popliteal fossa, and calf will be measured before and after each treatment. The operator supervising the procedure will be in constant visual and vocal contact with the subjects. For safety reasons, the systolic and diastolic blood pressure of each participant will be measured before and after treatment.

Rehabilitation program: The multidisciplinary rehabilitation program will consist of individual nutritional intervention, psychological support, and supervised physical activity throughout hospitalization. All patients will receive a balanced hypocaloric Mediterranean diet with 18-20 % proteins, 27-30 % fats (of which < 8% saturated fat) and 50-55 % carbohydrates (< 15% simple sugars), and 30 g of fibers from fresh vegetables. The diet plan will be organized by the hospital dietitian into three meals: breakfast, lunch, and dinner, with an energy distribution of 20 %, 40 % and 40 %, respectively. Two daily 60-minute physiotherapy sessions consisting of personalized progressive aerobic training, postural control exercises and progressive strengthening exercises were performed under the supervision of a physiotherapist. The first aerobic session performed in the morning after WBC consists of walking at a self-selected cadence. The second session performed in the afternoon consists of arm-cranking at an intensity of 65% of HRmax according to the Karvonen equation ((220 - age) × 0.65).

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Sequential
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • both sexes
  • age 18-65 yrs
  • BMI > 35 kg/m2

Exclusion Criteria

  • severe psychiatric conditions
  • acute respiratory disease
  • acute cardiovascular disease
  • unstable hypertension
  • cold intolerance
  • claustrophobia
  • pregnancy
  • recent modification of usual drug treatment
  • previous treatment with WBC
  • weight loss in the last 3 months
  • body temperature greater than 37.5°C.

Outcomes

Primary Outcomes

Change from baseline blood catecholamine levels (epinephrine, norepinephrine and dopamine)

Time Frame: up to 3 weeks

Catecholamine levels (ng/ml) in plasma samples will be measured at baseline and two weeks later, after multidisciplinary rehabilitation (R group) or multidisciplinary rehabilitation + WBC (RWBC group).

Secondary Outcomes

  • Change from baseline BMI(up to 4 weeks)
  • Change in skin temperatures after every session of WBC(up to 1 minute)
  • Change from baseline biochemical blood parameters HDL, LDL, Triglycerides and Glucose(up to 4 weeks)
  • Change from baseline biochemical blood parameter HBA1C%(up to 4 weeks)
  • Change from baseline weight(up to 4 weeks)
  • Change from baseline systolic blood pressure and diastolic blood pressure (mmHg)(up to 4 weeks)
  • Change from baseline heart rate variability (HRV) (bpm)(up to 4 weeks)
  • Change from baseline waist circumference(up to 4 weeks)
  • Change from baseline % of Fat Mass (FM), Free Fat Mass (FFM) and Muscle Mass (MM)(up to 4 weeks)
  • Change from baseline aerobic endurance(up to 4 weeks)
  • Change from baseline balance and functional mobility(up to 4 weeks)
  • Change from baseline in the sleep condition(up to 12 months)
  • Change from baseline of subjective sleepiness(up to 12 months)
  • Change from baseline in Depression, Anxiety and Stress(up to 12 months)
  • Change from baseline health status(up to 12 months)
  • Change from baseline isometric strength(up to 4 weeks)
  • Change from baseline of subjective well-being(up to 12 months)
  • Change from baseline of the conditions of patients with hip and knee osteoarthritis(up to 12 months)
  • Change from baseline of the use of pain medications(up to 12 months)
  • Change from baseline of the subjective quantification of the fear of movement(up to 12 months)
  • Change from baseline in intestinal function(up to 12 months)
  • Change from baseline Sleep Disturbance(up to 12 months)
  • Change from baseline of the obesity-related disability(up to 12 months)
  • Change from baseline of subjective sleep quality(up to 12 months)
  • Change from baseline in Central Sensitization Inventory (CSI)(up to 12 months)
  • Change from baseline of subjective psychological well-being(up to 12 months)
  • Change from baseline of the impact of fibromyalgia(up to 12 months)
  • Change from baseline of subjective pain level(up to 12 months)
  • Change from baseline of chronic pain(up to 12 months)
  • Change from baseline of subjective fatigue perception(up to 12 months)
  • Change from baseline in depression(up to 12 months)
  • Change from baseline in anxiety(up to 12 months)
  • Follow-up questionnaires or telephone interviews(up to 12 months)
  • Change from baseline Global Health(up to 12 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials